Zanubrutinib - BeiGene
Alternative Names: BGB-3111; BRUKINSALatest Information Update: 18 Jun 2024
At a glance
- Originator BeiGene
- Developer BeiGene; Medison Pharma
- Class Amides; Antineoplastics; Phenyl ethers; Piperidines; Pyrazoles; Pyrimidines; Small molecules; Urologics
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Phase III B-cell lymphoma
- Phase II/III Membranous glomerulonephritis
- Phase II CNS cancer; Diffuse large B cell lymphoma; Lupus nephritis; Lymphoma; SARS-CoV-2 acute respiratory disease
Most Recent Events
- 14 Jun 2024 Safety and efficacy data from a phase III trial in Chronic-lymphocytic leukaemia released by BeiGene
- 13 Jun 2024 Beigene and NewBridge Pharmaceuticals decides to conclude their distribution agreement of zanubrutinib in Middle East and Africa region
- 10 May 2024 Preregistration for Waldenstrom's macroglobulinaemia (Second-line therapy or greater) in Japan (PO), before May 2024 (Beigene pipeline, May 2024)